drugset / Trial / NCT00003007

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

NCT00003007

Phase 2 Completed University of Tennessee
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to determine the effectiveness of giving interferon alfa after chemotherapy and peripheral stem cell transplantation to patients who have stage III or stage IV multiple myeloma and who have been treated with high-dose melphalan.

Timeline

Start
1996-07
Primary completion
Completion
2004-01

Publications

  • Results Jones CM: Myeloablative therapy with interferon maintenance in multiple myeloma: high response rates and correlation with IL-6 and IL-6sR. J Investig Med 46(1): 12A 1998.

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule
Subject interferon alfa-2b Protein / enzyme biologic
Background Cyclophosphamide Other / unclassified Intravenous
Background Melphalan Small molecule
Background sargramostim Protein / enzyme biologic Subcutaneous

Indications